Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA study.
Front Transplant
; 2: 1264903, 2023.
Article
in En
| MEDLINE
| ID: mdl-38993866
ABSTRACT